PAOG CBD Nutraceutical Launch Timed To Capture Market Momentum
PAO Group, Inc. (OTC Pink: PAOG) plans to launch a CBD nutraceuticals line in 2021, aiming to capitalize on the booming CBD market, which is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027. The company is leveraging its patented cannabis extraction method for product development. PAOG management expects mainstream CBD initiatives to validate and enhance visibility for their products. The CBD nutraceuticals will be part of a long-term pharmaceutical strategy stemming from an acquisition of intellectual property from Nouveau Life Pharmaceuticals.
- Plans to launch a CBD nutraceuticals line expected to generate revenue in 2021.
- Leveraging patented cannabis extraction method for product development.
- The CBD market is projected to grow to $16.4 billion by 2027, presenting significant revenue potential.
- Potential technical complications may delay product implementation as outlined.
- Forward-looking statements carry risks and uncertainties that could affect anticipated results.
Sandusky, OH, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) has announced plans to soon launch a CBD nutraceuticals line of products expected to generate revenue this year, in 2021. Today the company highlights CBD industry momentum that could benefit PAOG’s impending CBD nutraceuticals product launch.
PAOG is developing CBD pharmaceutical and nutraceuticals from its intellectual property associated with a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
The 2020 CBD Nutraceuticals Market had an estimated value of
A recently published article on the growing CBD market highlights some “mainstream” company CBD initiatives the PAOG management views as beneficial to the PAOG CBD nutraceuticals product launch. PAOG management anticipates “mainstream” initiatives to validate their own products and even bring more attention to their products by simply bring more attention to the overall market.
Growing CBD Market Lures Mainstream Businesses
The article includes mention of Herbalife Nutrition, Procter & Gamble Co., Aurora Cannabis and recently IPO’d Grove, Inc.
PAOG’s CBD nutraceutical developments stem from the company’s long-term CBD pharmaceutical initiative built on a CBD intellectual property acquisition from Nouveau Life Pharmaceuticals.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
FAQ
What is PAOG's new product launch timeline for its CBD nutraceuticals?
What is the expected market growth for CBD products related to PAOG?
How is PAOG developing its CBD nutraceuticals products?
What are the risks associated with PAOG's forward-looking statements?
Which companies are influencing the CBD market that might benefit PAOG?
